Angela Sardaro | Immunotherapy | Excellence in Research

Published on by Top Pharmaceutical

Angela Sardaro | Immunotherapy | Excellence in Research

Assoc. Prof. Dr. Angela Sardaro at ASL Lecce, Italy.

Assoc. Prof. Dr. Angela Sardaro is a distinguished Italian academic and medical professional specializing in Radiotherapy and Diagnostic Imaging. She has served as a professor at the University of Bari Aldo Moro, coordinating degree programs and teaching across multiple disciplines, including Radiology, Oncology, and Medical Imaging. With over 15 years of academic experience, she has guided numerous theses and led scientific seminars. Dr. Sardaro’s prolific research output includes 81 indexed publications, an h-index of 15, and 842 citations 📈. Her contributions extend globally, with collaborations in the UK and Italy, reinforcing her impact in oncology and radiological science.

Publication Profile 

scopus

Education

Assoc. Prof. Dr. Angela Sardaro has demonstrated outstanding commitment to medical education 👩‍⚕️📚, coordinating the Degree Course in Radiologic Imaging and Radiotherapy Techniques at the University of Bari Aldo Moro 🎓. With over 15 years of teaching experience across various undergraduate and postgraduate programs, she has taught core disciplines like Radiotherapy, Radiobiology, and Diagnostic Imaging 🧬🔬. Her academic service spans doctoral programs, master’s training in pain therapy, and prestigious collaborations with institutions in Florence and the UK 🇮🇹🇬🇧. Dr. Sardaro has delivered 1,440 hours of lectures and 4,160 hours of professional training 📊, shaping future generations in radiological sciences.

Experience

Assoc. Prof. Dr. Angela Sardaro has made a remarkable impact on clinical education and hands-on training in radiological sciences 👩‍⚕️🧲. She has guided radiologic technologists, medical students, and postgraduates through innovative programs that incorporate cutting-edge technologies like PET/CT, proton therapy, and radiogenomics 💡🧬. Her dedication to advancing clinical competence is evident in the numerous experimental and clinical theses completed under her mentorship 📖🎓. By blending theory with real-world application, she has nurtured a generation of professionals equipped to meet the evolving challenges of diagnostic imaging and radiation therapy.

Research Focus 

Assoc. Prof. Dr. Angela Sardaro’s research focus lies at the intersection of oncologic radiotherapy, advanced diagnostic imaging, and radiation-induced toxicities 🎯🧲. Her work spans critical areas such as hypofractionated radiotherapy, prostate cancer, head and neck squamous cell carcinoma, breast cancer survivorship, and radiogenomics 📊🧬. She also investigates rare radiation-associated tumors like angiosarcomas, while leveraging cutting-edge tools like 18F-FCH PET/CT, MR imaging, and stereotactic radiosurgery 🧠🔬. Her systematic reviews and meta-analyses contribute to refining treatment protocols and improving patient outcomes 🩻👩‍⚕️. Dr. Sardaro’s impactful research bridges clinical innovation with evidence-based radiation oncology.

Publication Top Notes

  • Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead?
  • Nodal assessment and extranodal extension in head and neck squamous cell cancer: insights from computed tomography and magnetic resonance imaging
  • Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments
  • Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity
  • Radiation-Associated Angiosarcoma of the Breast: The State of the Art of a Rare and Aggressive Disease
  • Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis
  • Role of 18F-FCH PET/CT in Detecting Recurrences of Prostate Cancer After Curative Treatments

Sudeep Nagaraj | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Sudeep Nagaraj | Immunotherapy | Best Researcher Award

Dr. Sudeep Nagaraj, ICAR-NIVEDI, India

Dr. Sudeep Nagaraj is an accomplished molecular biologist and research scientist with a Ph.D. from GITAM University (2025) 🎓. He possesses extensive hands-on expertise in molecular genetics, cytogenetics, proteomics, virology, and phytochemistry 🧪🌿. With over six years of academic and research experience, he has served in various prestigious institutions including ICAR-NIVEDI and ICAR-IVRI 🏛️. Dr. Nagaraj has authored 20+ peer-reviewed publications on cytotoxicity, DNA barcoding, and viral epidemiology 📚. His primary research focus lies in virology and molecular diagnostics, especially lumpy skin disease in livestock 🐄🦠. He is known for blending academic rigor with applied research for public health impact 💡.

Publication Profile

Google Scholar

Education

Dr. Sudeep Nagaraj holds a Ph.D. in Molecular Biology from GITAM University (2025) 🧬, an MSc from SDUAHER, Tamaka Kolar (2016) 🧪, and a BSc from FGC, KGF (2012) 📚. His academic journey began at Chinmaya Vidyalaya, Kolar (SSLC, 2007) and continued through BGS PU College (PUC, 2009) 🏫. Professionally, he has accumulated diverse experience across esteemed research institutions and labs, contributing significantly to molecular and virology research 🧫. Additionally, he has one year of teaching experience in Molecular Biology at SIMS and RC, where he taught undergraduate students with dedication and clarity 🎓🧑‍🏫.

Experience

oDr. Sudeep Nagaraj has amassed rich experience through roles such as SRF at ICAR-NIVEDI (2021–present) 🧬, Young Professional-II at ICAR-IVRI (2020–2021) 🧫, and Research Scientist at Cytogene Diagnostics (2019–2020) 🔬. His journey also includes positions at SIMS and RC, QTLomics, and IDBR. He taught Molecular Biology at SIMS and RC for a year at the UG level 🎓. His hands-on skills span molecular genetics (PCR, DNA isolation, HRM), proteomics (SDS-PAGE, Bradford assay), cytogenetics (karyotyping), gene cloning, cell culture, virology (ELISA, virus titration), and phytochemistry (plant extract prep) 🧬🌿🧫.

Awards

Dr. Sudeep Nagaraj has been honored with several prestigious awards for his outstanding contributions to scientific research and innovation 🧠🔬. He received the Young Scientist Award at the International Conference on Science, Health, and Engineering held in Chennai on January 11, 2020 🏆. In 2021, he was conferred the Best Researcher Award at the International Research Awards on New Science Inventions on August 11 in Chennai 🥇. Most recently, in 2025, he was recognized once again with a Young Scientist Award from Scientific Laurels, celebrating his continued excellence in research 🚀📚.

Research Focus

Dr. Sudeep Nagaraj’s research centers around molecular virology, cytogenetics, and immunology, with a significant emphasis on Lumpy Skin Disease (LSD) in livestock 🐄. His work extends to plant-based cytotoxicity, DNA barcoding, and cell culture techniques, reflecting a strong interdisciplinary foundation 🌿🧪. His studies explore pathogen-host interactions, viral evolution, and molecular diagnostics, contributing vital insights into disease spillovers and viral epidemiology across species 🧠🔍. He also focuses on PBMC assays, ELISA, and nanoparticle toxicity, bridging biomedicine, virology, and phytochemistry. His impactful contributions aid in zoonotic disease management and therapeutic development 📊💉🌾.

Publication Top Notes

Lumpy Skin Disease (LSD) in Yak (Bos grunniens): An Evidence of Species Spillover from Cattle in India

Evaluation of In Vitro Cytotoxic Effects of Three Medicinal Plants on Peripheral Blood Mononuclear Cells (PBMC)

First evidence of lumpy skin disease in mithun (Bos frontalis) in India

An in vitro cytotoxic and genotoxic properties of Allamanda cathartica L. Latex green NPs on human peripheral blood mononuclear cells

Unravelling the genomic origins of lumpy skin disease virus in recent outbreaks

Evaluation of HCP5 and Chemokine C receptor type 5 gene polymorphisms in Indian psoriatic patients

DNA based identification of species of Zingiberaceae family plants using Bar-Hrm analysis

A SIMPLE, COST­EFFECTIVE, FAST AND EASY TO ISOLATE DNA PROTOCOL FROM HUMAN SAMPLES

Investigation of Comorbidity and Risk Analysis During Lumpy Skin Disease Outbreaks in India

Evaluation of invitro cytotoxic activity of parts of Murraya koenigii (curry) plant on human peripheral blood mononuclear cells

Separation and Optimisation of a Sucrose Density Gradient Centrifugation Protocol for Isolation of Peripheral Blood Mononuclear Cells (PBMC)

Fast and Easy Protocol of DNA Extraction from Fresh and Hard/Dried Plant Samples of Indian Spices

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Published on by Top Pharmaceutical

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Assist. Prof. Dr. Konstantinos Tsapakidis, University Hospital Of Larissa, Greece

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓👨‍⚕️ is an esteemed Medical Oncologist at the University of Thessaly, Greece. With a Ph.D. focused on prostate cancer research, he holds European Certification in Medical Oncology 🏅. Since 2018, he has been actively involved in clinical oncology, teaching postgraduate courses on cancer, diet, and immunotherapy 🍽️🧬. Dr. Tsapakidis has authored numerous impactful publications 📚, contributing significantly to cancer diagnostics and treatment. Passionate about education, he trains residents and nurses, advancing oncology knowledge. His expertise includes systemic antineoplastic therapies and immune-oncology 🌟.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓 is a dedicated Medical Oncologist with an impressive educational background. He earned his Biology degree from Aristotelian University of Thessaloniki 🧬 (1998–2002) and completed his Medicine degree at the University of Thessaly 🏥 (2003–2007). Dr. Tsapakidis achieved his Ph.D. with excellence (2005–2012), researching prostate cancer’s cell-cycle and apoptosis mechanisms 🔬. He specialized in Medical Oncology in 2017 🎯 and obtained the prestigious European Certification in Medical Oncology in 2018 🏅. He also enhanced his expertise through an Immune-Oncology e-learning program at the University of Piraeus in 2017–2018 💻.

Experience

Assist. Prof. Dr. Konstantinos Tsapakidis 💼 has extensive medical oncology experience. Since February 2025, he serves as Assistant Professor at the University of Thessaly 🎓. From 2018 to 2025, he worked as Consultant in Medical Oncology at University Hospital of Larissa 🏥. Previously, he was a University Scholar and Fellow Consultant there (2017–2018) 👨‍⚕️. He completed his residency in Medical Oncology (2014–2017) and earlier trained in Internal Medicine and Hematology at Larissa hospitals 🩺. Between 2008–2009, he was a Scientific Associate in Medical Oncology, laying a strong foundation for his clinical career 🔬.

Research Focus

Assist. Prof. Dr. Konstantinos Tsapakidis’s research focus lies primarily in Medical Oncology with a strong emphasis on cancer diagnosis, treatment, and immunotherapy. 🧬🩺 His work explores various cancer types including lung cancer, breast cancer, sarcomas, and rare cancers, investigating immunotherapy responses, molecular diagnostics, and tumor behavior. 🔬💉 He is particularly involved in studying biomarkers like PD-1/PD-L1, immune cell profiling, and novel therapeutic approaches to improve patient outcomes. 🧪⚕️ His research also covers cancer-associated complications like thrombosis and metastatic disease. Overall, his contributions advance personalized oncology care and innovative cancer treatment strategies.

Publication Top Notes

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature

The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers

Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients

ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

Combinatorial analysis of CD4<SUP>+</SUP>Tregs and CD8<SUP>+</SUP>Teff to predict response to ICI in patients with ES-SCLC

Metachronous Single Pulmonary Metastasis of Prostate Cancer: Report of a Rare Case and Literature Review

SYNCHRONOUS DIAGNOSIS OF TESTICULAR AND THYROID CANCER IN A YOUNG MALE

A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma COMMENT

Metastatic rectal cancer in the ampulla of Vater: A unique case

Radiotherapy and Breast Reconstruction: What Is the Ideal Timing? A Narrative Review

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Dr. Efthalia Zervoudi, Hellenic Pasteur Institute, Greece

Dr. Efthalia Zervoudi is a senior researcher at the Hellenic Pasteur Institute with a PhD in Biochemistry from the University of Athens. Her research focuses on designing inhibitors targeting antigen-trimming aminopeptidases, contributing significantly to immunology and cancer biology. She has extensive experience in oncology and molecular biomarkers, having held positions at Cardiff University and University Hospital “Attikon.” Dr. Zervoudi has authored multiple influential publications and holds patents on aminopeptidase inhibitors. She has received prestigious fellowships, including the Welcome Trust ISSF fellowship, and continues to advance personalized medicine through innovative molecular diagnostic approaches.

Publication Profile

Google Scholar

Education

I completed my PhD in Biochemistry at the University of Athens (2012–2016) with top honors, focusing on designing inhibitors targeting antigen-trimming aminopeptidases. Before that, I earned my Master’s degree in Biochemistry from the same university (2010–2012), studying the specificity pockets of aminopeptidases involved in antigen processing. My academic journey began with a Bachelor’s degree in Chemistry from the University of Patras (2003–2008), where I researched proteoglycans in cancer patients under Prof. Dimitrios Vynios. 🎓 Prior to university, I graduated high school with a strong average score of 18.5/20, marking the start of my scientific path.

Experience

Dr. Efthalia Zervoudi is currently serving as a Senior Researcher at the Hellenic Pasteur Institute (2024–present), contributing to cutting-edge biomedical research. From 2019 to 2023, she was a Research Coordinator at the Oncology Unit of University Hospital “Attikon” in Greece. 🏥 Previously, she held a postdoctoral research position at Cardiff University’s School of Medicine (2016–2019), specializing in Infection and Immunity. 🔬 Between 2010 and 2015, she collaborated with the Protein Chemistry Lab at the National Centre for Scientific Research “DEMOKRITOS”, working on the project: “Rational design and development of inhibitors for targeting antigen-trimming aminopeptidases.”

Awards

Dr. Efthalia Zervoudi has received several prestigious fellowships and awards recognizing her impactful research. In 2020, she was awarded funding by the Hellenic Society of Oncology for her study on Endoplasmic Reticulum Associated Peptidases as tools to understand cancer. 🧪 In 2015, she received the esteemed Wellcome Trust ISSF Fellowship at Cardiff University. 🇬🇧 Earlier, in Fall 2014, the Hellenic Academy of Athens honored her with the “Axillea and Aikaterini Dionysopoulou” award for her groundbreaking work on rationally designed inhibitors enhancing antigen presentation and cytotoxic T-cell responses. 🔬🎖️ Her research continues to push scientific boundaries.

Research Focus

Dr. Efthalia Zervoudi is a leading researcher in immunology and molecular biology, with a focus on antigen processing, immune regulation, and aminopeptidase function. Her work explores how enzymes like ERAP1 and ERAP2 trim antigenic peptides for presentation by MHC class I molecules, enhancing cytotoxic T-cell responses—a crucial process in cancer immunotherapy and autoimmune disease research. 🧬 She also develops targeted inhibitors to modulate immune responses, contributing to vaccine design and tumor immunity. 🧪 Her research bridges biochemistry, structural biology, and immuno-oncology, with potential applications in personalized medicine.

Publication Top Notes

Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses

Probing the S1 specificity pocket of the aminopeptidases that generate antigenic peptides

A common single nucleotide polymorphism in endoplasmic reticulum aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

Optimized peptide–MHC multimer protocols for detection and isolation of autoimmune T-cells

A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition

Autoimmune disease-associated variants of extracellular endoplasmic reticulum aminopeptidase 1 induce altered innate immune responses by human immune cells

3, 4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties

Novel selective inhibitors of aminopeptidases that generate antigenic peptides

Dual molecular mechanisms govern escape at immunodominant HLA A2-restricted HIV epitope

A common SNP in ER aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway

Correction: Konstantopoulos et al. HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway. Viruses 2024, 16, 113

Prof. Peng SHI|Immunotherapy|Best Researcher Award

Published on by Top Pharmaceutical

Prof. Peng SHI-Immunotherapy-Best Researcher Award

Prof. Peng SHI atCity University of Hong ,Hong Kong

Author Profile

Orcid

Early Academic Pursuits 🎓

Peng Shi’s academic journey began with a solid foundation in electrical engineering, earning a Bachelor of Engineering degree from Wuhan University, China, in 2002. His keen interest in blending engineering with biological systems led him to pursue advanced studies in biomedical engineering at Columbia University, USA, where he earned both an M.Phil. in 2006 and a Ph.D. in 2009. At Columbia, Dr. Shi honed his expertise in interdisciplinary research, laying the groundwork for his future contributions to translational neuro-engineering and bioelectronics.

Professional Endeavors 👨‍🏫

Dr. Shi’s career reflects a trajectory of academic excellence and innovation. After completing his Ph.D., he served as a Postdoctoral Fellow at the Department of Electrical Engineering, Massachusetts Institute of Technology (MIT), USA (2010–2011), where he worked alongside leading researchers to advance the frontiers of bioelectronics and synthetic biology.

In 2011, Dr. Shi joined the Department of Biomedical Engineering at the City University of Hong Kong as an Assistant Professor. His dedication and groundbreaking work earned him an early promotion to Associate Professor (with tenure) in 2016 and subsequently to Full Professor in 2020. Notably, these advancements highlight his exceptional contributions to his field within a remarkably short timeframe.

Contributions and Research Focus 🔬

Dr. Shi is a pioneer at the intersection of neuroscience and engineering, leveraging cutting-edge methodologies like nano-/micro-fabrication, bioelectronics, synthetic biology, high-resolution microscopy, and artificial intelligence. His research addresses critical challenges in translational neuro-engineering, emphasizing the development of high-throughput technologies and bioelectronic platforms to create innovative therapeutic systems.

His prolific output includes more than 90 publications in prestigious journals such as Nature Reviews Materials, Nature Biomedical Engineering, PNAS, Science Advances, and Advanced Materials. These works underscore his influence in fields spanning materials science, bioengineering, and neurotechnology. Beyond academic publishing, Dr. Shi has filed 18 patents, with several granted in the US and China. Some of these patents have served as the technological foundation for two biotech spin-offs, ANRim Biotechnology Limited and Electro-Ohmics, exemplifying the translational impact of his research.

Accolades and Recognition 🏅

Dr. Shi’s excellence in research and innovation has been recognized with numerous prestigious awards and appointments:

  • 2015: Awarded the 1000 Young Talent Program by the National Natural Science Foundation of China (NSFC), a testament to his exceptional potential in scientific leadership.
  • 2018: Received the Special Recognition for Young Scholars from the World Cultural Council for his contributions to advancing global scientific understanding.
  • 2022: Appointed as Associate Editor of Brain Research (Elsevier), reflecting his influence in shaping the field of neuroscience.
  • 2023: Selected for the Biology and Medicine Panel of the Hong Kong RGC Joint Research Schemes, recognizing his leadership in biomedical research.

Dr. Shi has also delivered over 100 invited talks at global conferences, workshops, and academic institutions, further solidifying his reputation as a thought leader.

Impact and Influence 🌍

Dr. Shi’s innovations have a far-reaching impact, bridging the gap between basic research and clinical applications. His high-throughput bioelectronic platforms are revolutionizing therapeutic strategies, particularly in the realm of neuro-engineering. The biotech companies he co-founded, such as ANRim Biotechnology Limited, have secured significant funding, including RMB15M in angel investments, and are valued at HKD70M, demonstrating his success in translating academic research into viable commercial solutions.

As a grant referee for organizations like the NSFC, European Research Council, and Hong Kong UGC, Dr. Shi contributes to shaping the global research landscape. His expertise is further acknowledged through his role as a manuscript reviewer for leading publishers such as Nature, Wiley, and Elsevier.

Legacy and Future Contributions 🌟

Dr. Peng Shi’s work is paving the way for the next generation of therapeutic technologies and bioelectronic systems. By fostering interdisciplinary collaborations and mentoring emerging scholars, he is shaping the future of biomedical engineering. His patents and spin-offs ensure that his innovations continue to benefit society, bridging the divide between academia and industry.

Looking forward, Dr. Shi is poised to expand his influence through groundbreaking discoveries in synthetic biology, neuro-engineering, and artificial intelligence, driving advancements in healthcare and enhancing human well-being. His legacy will undoubtedly inspire future researchers and innovators, cementing his status as a transformative figure in biomedical engineering.

Notable Publication

Multifunctional Hydrogel Electronics for Closed-loop Antiepileptic Treatment

  • Authors   :Yuan WANG; Guangyu ZHU; Shu Chen; Chenjie Xu; Kai Xie; Jin Qu; Peng SHI; xingdao he
  • Journal    : Science Advances
  • Year         :2024

Few-shot meta-learning applied to whole brain activity maps improves systems neuropharmacology and drug discovery

      • Authors   : Xuan Luo; Yanyun Ding; Yi Cao; Zhen LIU; Wenchong Zhang; Shangzhi Zeng; Shuk Han Cheng; Honglin Li; Stephen J
      • Journal    : iScience
      • Year         :2024

Integrated Piezoelectric Vascular Graft for Continuous Real-Time Hemodynamics Monitoring

  • Authors   : Zhiqiang Ma; Weibin Jia; Jing ZHANG; xingdao he; Shiyuan Liu; Mohamed Elhousseini Hilal; Xiang ZHOU
  • Journal    : Functional Materials
  • Year         :2024

Nanopores-templated CNT/PDMS Microcolumn Substrate for the Fabrication of Wearable Triboelectric Nanogenerator Sensors to Monitor Human Pulse and Blood Pressure

  • Authors   :Tao Zhang; Chuanjie Yao; Xingyuan Xu; Zhibo Liu; Zhengjie Liu; Tiancheng Sun; Shuang Huang.
  • Journal     : Materials Technologies
  • Year         :2024                                                                                                                                                                                                                                                                                                                                                                                                          

Deciphering the Temporal–Spatial Interactive Heterogeneity of Long Non-Coding RNAs and RNA-Binding Proteins in Living Cells at Single-Cell Resolution

  • Authors   : Deyuan Yang; Cheng Li; Yutong Kong; Yian Pei; Bing Miao; Gaole Dai; Pi Ding; Peng Shi; Zixun
  • Journal     : American Chemical Society
  • Year         :2024          

Dr. Annie Zhang|Immunotherapy|Best Researcher Award

Published on by Top Pharmaceutical

Dr. Annie Zhang|Immunotherapy|Best Researcher Award

Dr. Annie Zhang at Cambridge,United States

PROFILE  

 

Scopus

Dr. Annie Zhang embarked on her academic journey with a strong foundation in medicine and public health, earning an MD and an MPH. Her dual degrees equipped her with a nuanced understanding of clinical medicine and the critical public health frameworks essential for managing and preventing diseases at both population and individual levels. Driven by a commitment to advancing therapeutic options and improving patient outcomes, she honed her knowledge in both biostatistics and epidemiology. These skills have been foundational throughout her career, particularly in her roles focused on evidence generation and clinical research.

🌟 Professional Endeavors

Throughout her distinguished career, Dr. Zhang has held senior roles at prominent pharmaceutical companies, demonstrating her expertise in medical affairs, clinical research, and strategic evidence generation.

  1. Sanofi, Cambridge, MA
    As the Global Senior Medical Director in Immunology & Dermatology since 2018, Dr. Zhang has led impactful initiatives in Medical Evidence Generation within Global Medical Affairs. Her key achievements include winning Sanofi’s “Best of Best” award in 2023 and receiving a 1st Place Poster award at the American Academy of Dermatology (AAD) conference in 2024 for her work’s scientific importance. Her leadership has propelled Sanofi’s immunology initiatives, particularly through studies such as PEDISTAD and INFANTSTAD, which focus on disease modification and prevention of the atopic march.
  2. Apellis, Waltham, MA
    In her tenure as Medical Director at Apellis from January 2017 to December 2017, Dr. Zhang was responsible for strategic planning and clinical development in hematology, overseeing Phase II and III studies in conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA). Her role included extensive interaction with thought leaders and the clinical team to design and optimize trial strategies.
  3. Biogen, Cambridge, MA
    From 2009 to 2016, Dr. Zhang held several pivotal roles at Biogen, advancing from Medical Director in Global Medical Affairs to leading biostatistical teams for key drug programs like Tecfidera. She worked on Tysabri’s lifecycle management, supporting clinical trial design, data generation, and publication strategies, especially in multiple sclerosis (MS). Her expertise in biostatistics and clinical research design strengthened Biogen’s data-driven approaches, particularly in Phase III and IV clinical trials.
  4. PAREXEL International, Lowell, MA
    Dr. Zhang worked as a Senior Biostatistician at PAREXEL from 2007 to 2009, leading biostatistical tasks across diverse therapeutic areas, including oncology, CNS disorders, and cardiovascular disease. Her meticulous approach ensured the quality and accuracy of statistical reports for clinical trials, contributing to numerous successful projects within the biostatistics team.
  5. New England Research Institutes, Watertown, MA
    Early in her career, Dr. Zhang served as an Associate Research Scientist at NERI from 2000 to 2007, where she conducted critical statistical analyses for clinical research, laying the groundwork for her later expertise in biostatistics and clinical study design.

💡 Contributions and Research Focus

Dr. Zhang’s research has centered around dermatology, immunology, and hematology. At Sanofi, her work in immunology has led to groundbreaking insights on skin barrier integrity and neuroimmune function, providing essential evidence for the prevention of atopic march. She has also driven significant advancements in real-world evidence generation, particularly in cross-functional collaboration with global market access and regulatory teams, demonstrating her strategic alignment with organizational goals and patient needs.

🏆 Accolades and Recognition

Dr. Zhang’s achievements have earned her numerous accolades, including the prestigious “Best of Best” award at Sanofi in 2023. In addition, she received 1st Place at the AAD 2024 Poster Award for her study on skin barrier health. Her work has also made her one of the most-read and cited authors in Allergy and Pediatric Dermatology in 2024, underscoring her impact and visibility in her field.

🌐 Impact and Influence

Through her extensive collaborations, Dr. Zhang has influenced clinical practices and regulatory frameworks worldwide. Her involvement in key study proposals and evidence generation initiatives has significantly impacted the medical community’s understanding of dermatological conditions. Her efforts in strategic planning, data generation, and cross-functional teamwork have positioned her as an influential figure in dermatology and immunology, particularly in advancing therapies that meet rigorous safety and efficacy standards.

🌱 Legacy and Future Contributions

Dr. Zhang’s legacy lies in her innovative approach to medical evidence generation and her unwavering commitment to patient-centered research. Her leadership in studies such as PEDISTAD and INFANTSTAD has set new standards for clinical research in dermatology and immunology. As she continues her work at Sanofi, Dr. Zhang’s contributions promise to expand the understanding and treatment of complex immunological conditions, impacting healthcare practices on a global scale.

Through her career, Dr. Zhang has exemplified excellence, dedication, and a strategic vision, ensuring her place as a respected leader in the pharmaceutical and clinical research sectors. Her ongoing work will undoubtedly continue to shape medical innovations and patient care improvements, leaving a lasting legacy in the fields of immunology and dermatology.

🎓Publication 

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM

  • Authors   :Fox, R.J., Gold, R., Phillips, J.T., … Zhang, A., Marantz, J.L.
  • Journal    :Neurology and Therapy
  • Year         :2017

Number Needed to Treat in Multiple Sclerosis Clinical Trials

  • Authors   : Okwuokenye, M., Zhang, A., Pace, A., Peace, K.E.
  • Journal    :Neurology and Therapy
  • Year         :2017

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis

  • Authors   : Fox, R.J., Chan, A., Zhang, A., … Edwards, M.R., Marantz, J.L
  • Journal    :Current Medical Research and Opinion
  • Year         :2017

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

  • Authors   :Gold, R., Giovannoni, G., Phillips, J.T., … Zhang, A., Marantz, J.L.
  • Journal    :Neurology and Therapy
  • Year         :2016

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS

  • Authors   :Spelman, T., Kalincik, T., Jokubaitis, V., … Trojano, M., Butzkueven, H.
  • Journal    :Neurology: Clinical Practice
  • Year         :2016

Dr. Marc Bender|Immunotherapy |Best Researcher Award

Published on by Top Pharmaceutical

Dr. Marc Bender|Pharmaceutical Chemistry |Best Researcher Award|

Dr. Marc Bender at abriz University of Medical Sciences, Iran

PROFILE  

orcid

Early Academic Pursuits 📚

Marc Bender’s academic journey began with a strong foundation in molecular biology, earning a (link unavailable) and (link unavailable) from Universität Hamburg. He furthered his expertise by pursuing a doctorate in skin cancer research at the department of dermatology, Elbe Klinikum Buxtehude. His thesis focused on elucidating molecular mechanisms, particularly epigenetic regulation via miRNAs, involved in tumor progression of cutaneous squamous cell carcinoma.

Professional Endeavors 💼

As a data scientist, Marc contributed to the European melanoma registry (EUMelaReg), evaluating retrospective data for real-world clinical trials. This experience deepened his understanding of melanoma and immunotherapy, and he developed skills in statistical methods and programming. His professional endeavors have been marked by a commitment to advancing cancer research and treatment.

Contributions and Research Focus 🔬

Marc’s research focus encompasses various aspects of skin cancer, including:

– Investigating effects of combined UVA, UVB, visible light, and infrared radiation on human skin cells (KAUVIR)
– Examining the influence of UVA and UVB irradiation on human dermal stem cells (UV-DHDS)
– Comparing treatments for melanoma, including anti-PD1 monotherapy and BRAF/MEK inhibitor treatment (PDSeq and EMRSeq)
– Analyzing immune checkpoint inhibitor maintenance treatment after achieving a partial or complete response (EUMelaReg)

Accolades and Recognition 🏆

Marc’s work has been recognized through publications in esteemed journals, including:

– Journal of Cancer Research and Clinical Oncology
– Journal of Photochemistry and Photobiology B Biology
– Cancers (MDPI)
– Journal of Clinical Oncology (conference paper)
– Annals of Oncology (conference paper)

Impact and Influence 🌟

Marc’s research has contributed significantly to the understanding of skin cancer mechanisms and treatment options. His work has:

– Advanced knowledge of miRNA expression and its association with tumor progression
– Investigated treatment adherence in patients with stage III melanoma
– Compared outcomes of different treatment approaches for metastatic melanoma

Legacy and Future Contributions 🌱

As a dedicated researcher, Marc continues to contribute to the field of skin cancer research. His future endeavors will likely focus on:

– Furthering understanding of molecular mechanisms in skin cancer
– Developing innovative treatment approaches
– Collaborating with international researchers to advance cancer research

Marc’s legacy will be marked by his commitment to advancing cancer research, improving treatment options, and enhancing patient outcomes. His work will continue to influence the scientific community, inspiring future generations of researchers.

🎓Publication 

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

  • Authors   : Marc Bender
  • Journal    :Cancers
  • Year         :2022

UVB damage response of dermal stem cells as melanocyte precursors compared to keratinocytes, melanocytes, and fibroblasts from human foreskin

  • Authors   :Marc Bender
  • Journal    :Photochemistry and Photobiology B: Biology
  • Year         :2021

UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines

  • Authors   : Marc Bender
  • Journal    :Cancer Research and Clinical Oncologyy
  • Year         :2020

 

Assist Prof Dr. Hossam Hwihy|Immunotherapy |Best Researcher Award

Published on by Top Pharmaceutical

Assist Prof Dr. Hossam Hwihy, Immunotherapy ,Excellence in Innovation Awards

Assist Prof Dr. Hossam Hwihy at Faculty of science Al-Azhar University,Egypt

PROFILE  

scopus

 

Early Academic Pursuits 🎓

Dr. Hossam Mohammed Sayed Hwihy, an Egyptian national born on September 9, 1985, embarked on his academic journey with a deep passion for marine biology and environmental sciences. He completed his B.Sc. in Science with a specialization in Marine Biology from Al-Azhar University, Cairo, in 2007. His early academic pursuits were driven by a keen interest in understanding the complex interactions within marine ecosystems and the impact of human activities on these delicate environments. This foundational knowledge paved the way for his subsequent research in marine pollution and aquaculture, fields in which he would later make significant contributions.

To further his expertise, Dr. Hwihy pursued a Master’s degree in Marine Pollution at Al-Azhar University, graduating in 2018. His research during this period focused on the detrimental effects of pollutants on marine life, particularly how they affect aquatic organisms at the cellular and biochemical levels. His academic journey continued with a Ph.D. in Marine Biology from the same institution, which he completed in 2021. His doctoral research was instrumental in deepening his understanding of marine ecosystems and their responses to environmental stressors.

Professional Endeavors 💼

Dr. Hwihy’s professional career is marked by his dedication to both teaching and research in the field of marine biology and aquaculture. Starting as a Teaching Assistant in Zoology at Al-Azhar University in 2016, he quickly established himself as an enthusiastic and knowledgeable educator. He was involved in teaching a range of courses including Aquaculture, Fish Biology, Marine Pollution, and Seafood Processing to undergraduate students. His teaching philosophy emphasizes the practical application of theoretical knowledge, which has been well-received by his students.

In December 2021, Dr. Hwihy was appointed as a Lecturer and Postdoctoral Researcher at the Faculty of Science and Education, Al-Azhar University, Cairo. In this role, he has continued to contribute to the academic community through his teaching and research. Additionally, he is a founding member of the Al-Azhar Aquaponic Experimental Farm, a pioneering project that integrates aquaculture with hydroponics to create a sustainable food production system. This initiative highlights his commitment to advancing sustainable practices in aquaculture.

Contributions and Research Focus 🔬

Dr. Hwihy’s research contributions span several critical areas within marine biology and aquaculture. His primary research interests include:

  1. Aquaponics Management Systems: Dr. Hwihy has been at the forefront of research into aquaponics, a sustainable farming technique that combines aquaculture (raising fish) with hydroponics (growing plants without soil). His work focuses on optimizing these systems to enhance yield production while minimizing environmental impact.
  2. Nanotechnology in Aquatic Applications: He is actively involved in studying the effects of various nanomaterials on aquatic ecosystems, particularly how these materials can be used to address environmental challenges in aquaculture, such as pollution and disease management.
  3. Climate Change and Molecular Responses: Dr. Hwihy’s research also delves into the impacts of climate change on marine life, particularly at the molecular level. He is investigating how changes in temperature and other environmental factors influence the genetic and physiological responses of marine organisms.
  4. Marine Bioactive Materials and Toxins: His work in this area focuses on the application of marine-derived compounds in managing fish diseases and addressing environmental issues in aquaculture. This research is critical for developing new strategies to enhance the sustainability of fish farming.
  5. Artificial Intelligence in Aquaculture: Dr. Hwihy is exploring the use of artificial intelligence (AI) to improve the management of aquaculture systems. His research aims to develop AI-based tools for monitoring water quality, predicting fish health, and optimizing feeding strategies.

Accolades and Recognition 🏆

Throughout his career, Dr. Hwihy has been recognized for his contributions to marine biology and aquaculture. He has presented his research at numerous conferences and workshops, sharing his insights with the global scientific community. Notable among these is his presentation at the 9th International Conference for Basic Sciences (ISCAZ) in 2017, where he discussed the lethal toxicity of Profenofos and Sesbania sesban on freshwater snails. His work in this area has been published, further establishing his reputation as a researcher of note.

Dr. Hwihy has also been a caller and participant in various workshops, including those focused on aquaponics, nanotechnology, and the application of artificial intelligence in scientific research. His involvement in these events reflects his commitment to continuous learning and knowledge dissemination.

Impact and Influence 🌍

Dr. Hwihy’s work has had a significant impact on the field of aquaculture and marine biology, particularly in Egypt. His research on aquaponics and sustainable aquaculture practices has the potential to revolutionize food production in regions facing water scarcity and environmental degradation. By integrating innovative technologies such as nanotechnology and AI into aquaculture, he is helping to pave the way for more resilient and efficient farming systems.

His contributions extend beyond academia, as he actively engages in community outreach through workshops and seminars aimed at educating the public and industry stakeholders about the benefits of sustainable aquaculture. His role as a founding member of the Al-Azhar Aquaponic Experimental Farm is particularly noteworthy, as it serves as a model for future aquaculture projects in Egypt and beyond.

Legacy and Future Contributions 🚀

As a leading figure in the field of aquaculture and marine biology, Dr. Hwihy’s legacy is one of innovation and sustainability. His research has laid the groundwork for future advancements in sustainable food production, particularly in arid regions where traditional farming methods are less viable. His work in nanotechnology and AI is likely to have far-reaching implications for the future of aquaculture, making it more efficient and environmentally friendly.

🎓Publication 

Threat of heavy metal pollutants and parasites to freshwater fish with special reference to their risk of cancer to humans in Egypt

  • Authors   :Afifi, M.A.M., Radwan, M., Abbas, M.M.M., … Alabssawy, A.N., Khalaf-Allah, H.M.M.
  • Journal    :Aquaculture
  • Year         :2024

Biofloc biosecurity: A revolutionary paradigm in augmenting aquaculture health and resilience against Aeromonas hydrophila

    • Authors :Hwihy, H.M., Zeina, A.F., Abu Husein, M.S., El-Tabakh, M.A.M.
    • Journal   :Aquaculture and Fisheries
    • Year       : 2024

Evaluating of Pea Peels Meal as a Fishmeal alternative in Formulated Diet Ingredients of Oreochromis niloticus

UPLC/ESI/MS profiling of red algae Galaxaura rugosa extracts and its activity against malaria mosquito vector, Anopheles pharoensis, with reference to Danio rerio and Daphnia magna as bioindicators

  • Authors  :El-Tabakh, M.A.M., Elhawary, E.A., Hwihy, H.M., … Bakr, N.A., Shehata, A.Z.I.
  • Journal   :Malaria Journal
  • Year        :   2023

DNA Barcoding and Sensitivity of Dengue Vector Aedes aegypti (Linnaeus, 1762) (Diptera: Culicidae) Aquatic Stages to Different Insecticides with Reference to Non-Target Organisms, Danio rerio and Daphnia magna